NBE Therapeutics
Florian Durante has worked for a number of companies since 2014. In that year, they began a commercial apprenticeship with Syngenta, where they gained experience in three departments. From 2017-2020, they held the role of Accounting Specialist at Bank CIC |Switzerland|, followed by HR-Controlling Specialist at Universitäre Psychiatrische Kliniken Basel from 2018-2022. In 2022, they began working as Financial Controller for NBE-Therapeutics AG, Amal Therapeutics, and Boehringer Ingelheim.
Florian Durante completed a Bachelor of Science in Business Administration from the University of Applied Sciences and Arts Northwestern Switzerland FHNW from 2018 to 2022. Prior to that, they obtained a Kaufmann/-frau EFZ, M-Profil from Handelsschule KV Basel from 2014 to 2017.
This person is not in any teams
This person is not in any offices
NBE Therapeutics
1 followers
NBE-Therapeutics is developing best-in-class cancer therapies to increase survival and improve quality of life for cancer patients worldwide. The company’s next-generation immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate (ADC) platform. This best-in-class ADC platform creates highly potent and safe immune-stimulatory ADCs ("iADCs™") with an anthracycline payload, not only directly targeting tumor cells, but also inducing a long-lasting immunological anti-tumor effect. The company’s lead asset, NBE-002, an anti-ROR1 ADC, is due to start first-in-human clinical trials in three US centers by the end of 2020, focusing on triple negative breast cancer, but also other solid cancer indications which express ROR1. NBE-Therapeutics is a privately owned biotech company based in Basel, financed by Germany’s Boehringer Ingelheim Venture Fund, the Czech Republic’s PPF Group and Denmark’s Novo Holdings as international institutional investors, and by Swiss, German, and Dutch private investors. The company has raised over USD 65m, including a USD 22m Series C (2020), two USD 20m Series B rounds (2016 & 2018), a USD 3m Series A (2015), and over USD 4m from several non-dilutive grants from organizations including the Swiss Commission for Technology & Innovation, the European Commission, and Systems-X.